Accuray at ESTRO 2023 | Booth 250
As healthcare providers face unprecedented changes, certainty matters more than ever. At ESTRO 2023, see how our advanced technology can help give clinicians the tools to achieve best-in-class clinical workflows for a full spectrum of clinical indications. How clinical evidence gives patients greater certainty that they’re getting the best possible treatment. And how that combination of powerful technology and clinical evidence give healthcare organizations greater certainty to make confident investments to drive future success.
The Radixact® System, a Comprehensive
Breast Cancer System
Visit Accuray ESTRO booth #250 to see how the innovative VitalHold* Breast Package gives clinicians the certainty to treat virtually all breast cancer cases with the Radixact System — maximizing patient comfort and optimizing patient outcomes.
Advances in Hypofractionation for Breast and Prostate Cancer
The Accuray Symposium features leading clinical experts discussing the most recent and promising clinical research on hypofractionated radiotherapy treatments for breast and prostate cancers.
Opening & Closing Insights on Hypofractionation
Dr. Seth Blacksburg, SVP, Chief Medical Officer, Accuray
Prof. Barbara Alicja Jereczek-Fossa, Full Professor of Radiation Oncology, University of Milan and Chair of Division of Radiation Oncology of European Institute of Oncology, Milan, Italy
From the Crystal Study with Extreme Hypofractionation to Moderate Hypofractionation
Dr. Maria Cristina Leonardi, Deputy Director, Division of Radiotherapy, IEO European Institute of Oncology, Milan, Italy
What We Have Learnt from PACE Multicenter, International Phase 3 Randomized Controlled Study
Prof. Nicholas van As, Medical Director and Consultant Clinical Oncologist of The Royal Marsden NHS Foundation Trust and Professor in Precision Prostate Radiotherapy at The Institute of Cancer Research, London and Lead Investigator of the PACE Trial